News Search Results
Mar 03, 2025, 11:36 ET Myosin Therapeutics Closes Second Seed Round to Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3
More news about: Myosin Therapeutics Inc.
Mar 03, 2025, 10:45 ET Luxury Vinyl Tile (LVT) Flooring Market Size to Hit US$ 43.74 Billion by 2031 Driven by Rising Residential Construction, The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Mar 03, 2025, 10:30 ET Colloidal Silica Market Size to be Worth US$ 885.18 Million by 2031 Exclusive Report by The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners
Mar 03, 2025, 10:19 ET SynerFuse™ Proof-of-Concept Study Completed
About RQM+RQM+ accelerates medical innovation by streamlining the lifecycle of devices, diagnostics, and biotechnology products. Our expertise transforms innovative ideas into market-ready solutions, ensuring life-changing technologies reach patients faster and more
More news about: SynerFuse
Mar 03, 2025, 09:17 ET VIVICI LAUNCHES NEW STANDARD OF PROTEIN IN US MARKET
fermentation – the method used by Vivici to create dairy protein - combines the process of traditional fermentation with the latest advances in biotechnology, producing proteins without the need for animals. The technology promises to sustainably meet the protein needs of the world's growing population,
More news about: Vivici B.V.
Mar 03, 2025, 09:08 ET ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Mar 03, 2025, 09:00 ET Coronado Research Announce the Appointment of Stephen Ralston as EVP Market Access and HEOR
Coronado Research, a consultancy-led, professional services organisation providing support to pharmaceutical, biotechnology, and medical device companies, has appointed Stephen Ralston as EVP Market Access and Health Economics Outcomes Research
More news about: Coronado Research
Mar 03, 2025, 09:00 ET Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
SINGAPORE, March 3, 2025 /PRNewswire/ -- Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch
More news about: Callio Therapeutics
Mar 03, 2025, 09:00 ET Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
SINGAPORE, March 3, 2025 /PRNewswire/ -- Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch
More news about: Callio Therapeutics
Mar 03, 2025, 08:35 ET skinbetter science® Launches BioRewind Skin Health Dietary Supplement to Combat Skin Glycation
aging. Without intervention, glycated collagen accumulates at an average annual rate of 3.7%.2 BioRewind leverages proprietary CORExtract biotechnology comprises of rosemary extract and potent bioactive co-factors which help reverse the cumulative effects of early-stage glycation and skin aging
More news about: skinbetter science
Mar 03, 2025, 08:00 ET Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Pam Garzone, Chief Development Officer
More news about: Anixa Biosciences, Inc.
Mar 03, 2025, 07:45 ET Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
this study indicates this may be possible. About Latigo BiotherapeuticsLatigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that directly target the source of pain. Latigo's
More news about: Latigo Biotherapeutics
Mar 03, 2025, 07:00 ET Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen
Mass., March 3, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, today announced that Ipsen (Euronext: IPN;
More news about: Marengo Therapeutics
Mar 03, 2025, 06:30 ET Immunic to Participate in Scientific and Investor Conferences in March
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Mar 03, 2025, 05:45 ET Class Action Filed Against ICON Public Limited Company (ICLR) - April 11, 2025 Deadline to Join - Contact The Gross Law Firm
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Mar 03, 2025, 03:20 ET METiS Pharmaceuticals Appoints Mark Herbert as Chief Business Officer
March 3, 2025 /PRNewswire/ -- METiS Pharmaceuticals, a clinical-stage, AI-driven biotechnology company specializing in innovative drug delivery technologies, today announced the appointment of Mark Herbert as
More news about: METiS Pharmaceuticals
Mar 03, 2025, 02:00 ET BioRes Ruizhi BLC Implant System Showcased in China, Addressing Rising Demand for High-quality Implants
cutting-edge technology and innovation, supporting oral health professionals and enhancing patient outcomes worldwide. About Chengdu Besmile Biotechnology Co., Ltd. Besmile specializes in dental CAD/CAM materials, equipment, and implant systems, delivering cutting-edge digital solutions
More news about: Besmile
Mar 03, 2025, 01:11 ET AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 260 employees
More news about: AbbVie
Mar 02, 2025, 20:54 ET Azzur Group ("Azzur") Reaches Agreement to Sell Consulting Business for $56 Million to ELIQUENT Life Sciences
enterprises. With nearly four decades of service to the life science community, we have become a trusted partner to the world's leading pharmaceutical, biotechnology, medical device, and healthcare companies, as well as their supply chain. For more information, visit
More news about: Azzur Group
Mar 01, 2025, 18:09 ET ICLR Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)
insufficient to shield the company from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 01, 2025, 17:30 ET POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Mar 01, 2025, 09:06 ET China committed to open sci-tech cooperation for benefits of all
worldwide. As a new wave of scientific and industrial revolution surges, breakthroughs in artificial intelligence, quantum computing, and biotechnology are reshaping the global landscape. Nations universally seek to harness technological innovation as an engine for economic vitality. Yet, amid rising
More news about: People's Daily
Feb 28, 2025, 23:00 ET ICLR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ICON PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Feb 28, 2025, 16:01 ET AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Feb 28, 2025, 11:45 ET Aquafeed Market Size to Reach US$ 103.15 Billion by 2031 Driven by Growing Aquaculture Industry | Exclusive Report by The Insight Partners
consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact
More news about: The Insight Partners